Cleaved-CTSZ (L62) Antibody

What is Cleaved-CTSZ (L62) Antibody and what epitope does it recognize?

Cleaved-CTSZ (L62) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of fragment of activated Cathepsin Z protein resulting from cleavage adjacent to L62. The antibody recognizes the amino acid range 43-92 of human Cathepsin Z (CTSZ). The antiserum is produced against a synthesized peptide derived from human CATZ at this specific amino acid range . The specificity for the cleaved form makes this antibody valuable for studying the activation state of Cathepsin Z in research contexts.

What is Cathepsin Z and what are its known biological functions?

Cathepsin Z (also known as Cathepsin P or Cathepsin X) is a lysosomal cysteine protease and member of the peptidase C1 family. It exhibits both carboxy-monopeptidase and carboxy-dipeptidase activities and is capable of producing kinin potentiating peptides . Functionally, CTSZ is responsible for the adhesion and migration of both immune and tumor cells . It plays a role in modifying molecules such as lymphocyte function-associated antigen (LFA-1), focal adhesion kinase (FAK), and SRC kinase, which affects cell morphology and promotes cell migration . This enzyme is regularly expressed by immune cells including monocytes, macrophages, and dendritic cells .

What are the validated species reactivity and applications for this antibody?

Based on manufacturer specifications, Cleaved-CTSZ (L62) Antibody demonstrates reactivity with human and monkey samples . The antibody has been validated for Western Blot (WB) and ELISA applications with the following recommended dilutions:

• Western Blot: 1:500-1:2000

• ELISA: 1:5000

Western blot validation has been performed using COS7 cells with positive detection of the cleaved form of Cathepsin Z .

What are the optimal storage and handling conditions for Cleaved-CTSZ (L62) Antibody?

For optimal stability and activity maintenance, Cleaved-CTSZ (L62) Antibody should be stored at -20°C for up to one year from the date of receipt . For short-term storage and frequent use, some manufacturers recommend storing at 4°C for up to one month . It is important to avoid repeated freeze-thaw cycles as this can compromise antibody performance . The antibody is typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability during storage .

How should researchers optimize Western Blot protocols when working with Cleaved-CTSZ (L62) Antibody?

When using Cleaved-CTSZ (L62) Antibody for Western Blot analysis, researchers should consider the following protocol optimizations:

• Sample preparation: Ensure proper cell lysis and protein extraction from human or monkey samples.

• Gel concentration selection: The cleaved form of Cathepsin Z has an observed band at approximately 27 kDa , so an appropriate polyacrylamide gel concentration should be selected.

• Antibody dilution: Begin with a 1:1000 dilution within the recommended range (1:500-1:2000) and adjust based on signal intensity.

• Blocking: Use a 5% BSA or non-fat milk solution in TBST to minimize background.

• Positive controls: Include COS7 cells which have been validated to express cleaved Cathepsin Z detectable by this antibody .

• Incubation times: Typically overnight incubation at 4°C yields optimal results for primary antibody binding.

• Detection system: Choose appropriate secondary antibodies and detection reagents compatible with rabbit IgG.

What considerations should be made when designing ELISA experiments with this antibody?

For ELISA applications using Cleaved-CTSZ (L62) Antibody, researchers should consider:

• Antibody dilution: Begin with the recommended 1:5000 dilution .

• Antigen concentration: Optimize coating concentration of target protein or peptide.

• Blocking buffer: Test different blocking agents to minimize background while maintaining specific binding.

• Sample types: Consider whether the antibody will detect natural or denatured forms of the protein depending on ELISA format (direct, indirect, sandwich, or competitive).

• Detection system: Select appropriate enzyme-conjugated secondary antibodies and substrates.

• Controls: Include both positive and negative controls to validate results.

• Standard curve: Develop a standard curve using recombinant Cathepsin Z protein if quantification is required.

How can Cleaved-CTSZ (L62) Antibody be utilized in cancer research?

Cleaved-CTSZ (L62) Antibody offers several valuable applications in cancer research:

• Biomarker investigation: CTSZ has been identified as a potential biomarker for prostate cancer (PCa), with decreased CTSZ mRNA levels in blood cells of PCa patients compared to healthy subjects .

• Tumor microenvironment analysis: The antibody can be used to study the role of cleaved Cathepsin Z in immune cell infiltration, as CTSZ is involved in T cell migration through modulation of LFA-1 .

• Cell migration studies: Cathepsin Z plays a role in cell adhesion and migration, which are critical processes in cancer metastasis .

• Dual-role investigation: Research indicates that CTSZ has both pro- and anti-tumorigenic effects depending on the site of expression. The antibody can help distinguish between these contexts by identifying where cleaved CTSZ is expressed .

• Prognostic marker evaluation: Low levels of CTSZ mRNA in blood have been associated with biochemical relapse in PCa patients, suggesting potential prognostic value .

What cell models and experimental systems have been validated for research with this antibody?

Based on the available information:

• COS7 cells have been validated for Western Blot analysis using Cleaved-CTSZ (L62) Antibody .

• Human and monkey samples show reactivity with this antibody .

• Blood cells have been used in studies of CTSZ mRNA expression in the context of prostate cancer research .

Researchers should consider these validated systems when designing experiments, while also potentially exploring other relevant cell lines and tissues based on their specific research questions.

How might researchers investigate the relationship between Cathepsin Z cleavage and immune cell function?

To study the relationship between Cathepsin Z cleavage and immune cell function, researchers could design experiments that:

• Isolate primary immune cells (monocytes, macrophages, dendritic cells, and T cells) from human blood and analyze the expression and cleavage status of CTSZ using the Cleaved-CTSZ (L62) Antibody via Western Blot.

• Perform cell migration assays with immune cells while monitoring CTSZ cleavage status to correlate functional outcomes with processing status.

• Design co-culture experiments with immune and tumor cells to investigate how CTSZ cleavage affects immune cell infiltration and anti-tumor activity.

• Use RNA interference or CRISPR-Cas9 to modulate CTSZ expression in immune cells, followed by functional assays and detection of the cleaved form using the antibody.

• Analyze tissue sections from tumor samples for immune infiltrates and correlate with cleaved CTSZ expression patterns using immunohistochemistry techniques.

What is the current understanding of the dual role of Cathepsin Z in tumorigenesis?

Current research suggests that Cathepsin Z has a context-dependent dual role in cancer:

• As an anti-tumor factor: In healthy subjects, immune cells in the blood express high levels of CTSZ mRNA . This expression appears to be important for immune cell migration and function, potentially enhancing anti-tumor immune responses. The decreased expression of CTSZ mRNA in blood cells of prostate cancer patients (75% lower than healthy subjects) suggests a potential protective role of CTSZ in immune cells .

• As a pro-tumor factor: CTSZ is overexpressed in several types of primary tumors, including prostate, colorectal, gastric, liver, melanoma, and pancreatic neuroendocrine tumors . In these contexts, CTSZ appears to promote tumor cell adhesion and migration through the extracellular matrix, potentially facilitating metastasis .

This dual role highlights the importance of considering the site of CTSZ expression when interpreting research findings. Cleaved-CTSZ (L62) Antibody can help researchers distinguish between these different contexts by identifying the activated form of the enzyme in various cell types.

How does the cleavage status of Cathepsin Z affect its biological activity in different cellular contexts?

The cleavage of Cathepsin Z at L62 represents an activation step that influences its biological functions:

• In immune cells: Cleaved Cathepsin Z modifies the lymphocyte function-associated antigen (LFA-1), changing cell morphology and promoting cell migration . This process is crucial for T cell spreading and infiltration into tissues, including tumor sites.

• In adhesion and migration processes: The activated form of CTSZ interacts with integrin receptors to facilitate cell movement through the extracellular matrix . This has implications for both immune cell trafficking and tumor cell dissemination.

• Enzymatic activity: Cleaved CTSZ exhibits both carboxy-monopeptidase and carboxy-dipeptidase activities , with the potential to cleave and activate various substrate molecules, including kinins and other signaling proteins.

• Regulatory functions: Cleavage may affect interactions with focal adhesion kinase (FAK) and SRC kinase, influencing downstream signaling pathways that control cell behavior .

Researchers using Cleaved-CTSZ (L62) Antibody can investigate these context-specific effects by comparing the presence of cleaved versus uncleaved forms in different cell types and experimental conditions.

What are the implications of Cathepsin Z as a potential biomarker for prostate cancer diagnosis?

Research has revealed several important implications regarding Cathepsin Z as a prostate cancer biomarker:

• Diagnostic potential: CTSZ mRNA in blood cells demonstrated an area under the curve (AUC) of 0.832 for PCa diagnosis, with 93.3% specificity and a positive likelihood ratio (+LR) of 9.4 .

• Complementary to PSA: While CTSZ mRNA shows similar sensitivity and negative likelihood ratio (-LR) to PSA (approximately 0.4), its high specificity and +LR suggest it could serve as a valuable complement to PSA testing .

• Potential to reduce unnecessary biopsies: The high specificity of CTSZ mRNA expression could help confirm positive PCa diagnosis in patients with slightly elevated PSA, potentially eliminating unnecessary biopsies and their associated risks .

• Prognostic value: Lower levels of CTSZ mRNA were found in patients who experienced biochemical relapse, suggesting potential value as a prognostic indicator .

• Mechanism considerations: The site of CTSZ expression appears fundamental to its role as either a protective factor (in blood cells) or a malignant determinant (in tumors) .

This research suggests that investigating cleaved Cathepsin Z using specific antibodies could further enhance understanding of its biomarker potential and functional role in cancer progression.

What are common issues encountered when using Cleaved-CTSZ (L62) Antibody and how can they be resolved?

When working with Cleaved-CTSZ (L62) Antibody, researchers might encounter several technical challenges:

• Low signal in Western Blot:

  • Solution: Increase antibody concentration within the recommended range (1:500-1:2000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize protein loading amounts (25-50 µg per lane)

  • Use enhanced chemiluminescence (ECL) detection systems with higher sensitivity

• High background:

  • Solution: Increase blocking time and concentration (5% BSA or milk in TBST)

  • Increase washing steps duration and number

  • Reduce secondary antibody concentration

  • Try alternative blocking agents (casein, fish gelatin)

• Non-specific bands:

  • Solution: Increase the stringency of washing conditions

  • Optimize antibody dilution

  • Pre-adsorb the antibody with non-specific proteins

  • Consider using gradient gels to better separate proteins of similar size

• Inconsistent results between experiments:

  • Solution: Standardize protein extraction methods

  • Use consistent cell culture conditions

  • Prepare fresh working solutions of antibodies for each experiment

  • Include appropriate positive controls (e.g., COS7 cells)

How can researchers validate the specificity of their Cleaved-CTSZ (L62) Antibody results?

To confirm the specificity of Cleaved-CTSZ (L62) Antibody results, researchers should implement the following validation strategies:

• Positive controls: Include COS7 cells or other validated samples known to express cleaved Cathepsin Z .

• Negative controls: Use cells with CTSZ knockdown or knockout as negative controls to confirm antibody specificity.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide (from the 43-92 amino acid region of human CATZ) to block specific binding sites before probing samples.

• Multiple detection methods: Confirm findings using complementary techniques (e.g., if using Western Blot, validate with ELISA or immunofluorescence).

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight of approximately 27 kDa for cleaved Cathepsin Z .

• Correlation with mRNA expression: When possible, correlate protein detection results with CTSZ mRNA expression data from qRT-PCR.

• Cross-validation with other antibodies: Compare results with other validated antibodies against different epitopes of Cathepsin Z to build confidence in specificity.

How might Cleaved-CTSZ (L62) Antibody contribute to understanding immune infiltration in tumors?

Cleaved-CTSZ (L62) Antibody could advance research on immune infiltration in tumors through several approaches:

• Tumor microenvironment analysis: The antibody can be used to identify activated Cathepsin Z in tumor-infiltrating lymphocytes (TILs) and correlate with clinical outcomes. This is particularly relevant given that CTSZ can improve adhesion and migration of T cells through endothelia, potentially increasing levels of tumor-infiltrated CD8 T cells, which is a known marker of good prognosis in various cancers .

• Mechanistic studies: Researchers can investigate how cleavage of CTSZ affects LFA-1 modification and subsequent T cell migration into tumor tissues, potentially revealing new therapeutic targets to enhance immune infiltration.

• Comparative studies: By analyzing cleaved CTSZ expression in both blood immune cells and tumor tissues, researchers can better understand the dual role of this enzyme in cancer progression and immune response.

• Therapeutic response prediction: Expression patterns of cleaved CTSZ in immune cells could potentially predict response to immunotherapies that rely on effective immune cell infiltration into tumors.

• Development of novel biomarkers: Combining cleaved CTSZ detection with other immune markers could lead to more comprehensive biomarker panels for cancer diagnosis and prognosis.

What novel methodologies could incorporate Cleaved-CTSZ (L62) Antibody for cancer research?

Innovative methodologies that could leverage Cleaved-CTSZ (L62) Antibody include:

• Single-cell analysis techniques: Combining the antibody with single-cell technologies to identify specific immune cell subpopulations expressing cleaved CTSZ and correlate with functional characteristics.

• Liquid biopsy development: Building on findings that CTSZ mRNA in blood cells has diagnostic potential for prostate cancer , researchers could develop antibody-based liquid biopsy approaches targeting cleaved CTSZ protein.

• Multiplexed imaging: Incorporating the antibody into multiplexed immunofluorescence or mass cytometry panels to simultaneously analyze cleaved CTSZ expression alongside other cancer and immune markers in tissue sections.

• In vivo imaging approaches: Developing labeled versions of the antibody for non-invasive tracking of cleaved CTSZ-expressing cells in preclinical models.

• Therapeutic targeting strategies: Using the antibody to identify and validate specific cleavage sites as potential targets for therapeutic intervention in cases where CTSZ activity promotes tumor progression.

• Biomarker panels: Integrating cleaved CTSZ detection into multi-parameter assays alongside other established biomarkers such as PSA for improved cancer diagnosis and monitoring.

How does the detection of cleaved Cathepsin Z compare with measurement of total Cathepsin Z in research applications?

Understanding the distinctions between detecting cleaved versus total Cathepsin Z provides important methodological considerations:

What are the most appropriate experimental controls when working with Cleaved-CTSZ (L62) Antibody?

A comprehensive experimental design with appropriate controls is essential for generating reliable data with Cleaved-CTSZ (L62) Antibody:

Implementing these controls systematically will enhance data reliability and facilitate accurate interpretation of experimental results when using Cleaved-CTSZ (L62) Antibody.